Sector News

EuroAPI appoints new Executive Committee members

December 3, 2023
Life sciences

EUROAPI (Paris:EAPI) today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee.

In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company’s ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023.

“David brings extensive and international experience in industrial operations, with a particular focus on large transformation of organizations. His expertise will be instrumental in our ambition to adapt the company’s operating model in a rapidly evolving environment,” said Viviane Monges, EUROAPI’s Chief Executive Officer. “David and Marion add great value to our Executive Committee. I also want to use this opportunity to thank Eric for his many contributions to the creation, listing and management of EUROAPI.”

David Seignolle, Chief Operating Officer

David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management.

Marion Santin, Chief Legal, Compliance, and IP Officer

Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I – Panthéon-Sorbonne. Marion is also a member of the Paris Bar.

Source: businesswire.com

comments closed

Related News

February 17, 2024

GSK concludes Aiolos Bio acquisition for $1.4bn

Life sciences

The agreement, signed last month, includes an upfront payment of $1bn and $400m in regulatory milestone payments. The acquisition introduces AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, into GSK’s pipeline.

February 17, 2024

CRISPR gene therapy Casgevy secures approval in Europe

Life sciences

Vertex Pharmaceuticals and CRISPR Therapeutics have scored another regulatory approval for Casgevy (exagamglogene autotemcel) after the European Commission granted conditional marketing authorisation to the gene therapy.

February 17, 2024

Gilead to buy liver drugmaker CymaBay for $4.3 Billion

Life sciences

US biopharmaceutical company Gilead Sciences is to acquire CymaBay Therapeutics for $4.3 billion. Gilead offered to purchase all outstanding shares of CymaBay for $32.50 per share in cash. CymaBay, based in the US near San Francisco, California, has developed the investigational drug seladelpar, which is currently in clinical Phase 3.

How can we help you?

We're easy to reach